healthNewsغير مصنف

AbbVie settles Humira biosimilar dispute with Fresenius Kabi

U.S. drugmaker AbbVie Inc said on Thursday it has settled a patent dispute regarding its Humira biosimilar with Fresenius Kabi Oncology Ltd and will grant the Germany-based company non-exclusive marketing rights for the drug.

اظهر المزيد

مقالات ذات صلة

زر الذهاب إلى الأعلى